Progress in Preclinical and Clinical Research on Reduning Injection in Treatment of COVID-19
During public welfare period, this lecture has attracted 188 visitors and learners.
中文语音&英文字幕/Chinese voice & English subtitles
Cao Liang, senior engineer, is mainly engaged in the development of new drugs. He has successively obtained good manufacturing practices (GMP) certificates from the National Medical Products Administration (NMPA) for 10 new TCM drugs. As the major inventor, he has filed 84 patents, 35 of which have been authorized. He has also published more than 100 papers in core journals, including 27 recorded by SCI. He has won multiple national and provincial awards, such as the National Science and Technology Progress Award.
Reduning Injection, composed of Herba Artemisiae Annuae, Flos Lonicerae, and Fructus Gardeniae, is applicable to the treatment of viral respiratory infections. After the outbreak of coronavirus disease 2019 (COVID-19) in China, a randomized, open-labeled, multi-center, controlled trial was conducted to explore the efficacy of Reduning Injection in the treatment of COVID-19. The results showed that Reduning Injection shortened the median time to resolution of the clinical symptoms, reduced the time required for nucleic acid test turning negative and hospital stay, increased the recovery rate, improved hematological indices, and decreased the deterioration rate.
双语版/Bilingual edition: http://jtp.cnki.net/bilingual/EBook/Detail?pykm=TCMC
中文版/Chinese edition: https://book.oversea.cnki.net/CCGBWEB/Book/Detail/OB200803001
英文版/English edition: https://book.oversea.cnki.net/CCGBWEB/Book/Detail/OB200803002
Distinguished Editor-in-Chief and editorial board members: Editor-in-Chief HUANG Luqi is the academician of Chinese Academy of Engineering and president of China Academy of Chinese Medical Sciences. The Editorial Board includes 17 professors and chief physicians from Chinese Academy of Sciences, China Academy of Chinese Medical Sciences, and first-class hospitals in China.
Strict quality control: All 70 papers are strictly selected from nearly 800 online-first papers about COVID-19 treatment with TCM by the experts organized by China Association of Chinese Medicine and National Administration of Tradition Chinese Medicine.
Authoritative resources of anti-epidemic achievements by TCM: The papers involve the latest TCM clinical practice in the first-line treatments, cover various COVID-19 cases, age groups, regions, and complications, and include different effective TCM treatments. They possess universal guiding significance to clinical treatment of COVID-19 worldwide.
电子书可在网站注册下单或联系销售人员订购/Place your order on website or contact with our sales managers